Compare · DRNA vs NEOS
DRNA vs NEOS
Side-by-side comparison of Dicerna Pharmaceuticals, Inc. (DRNA) and Neos Therapeutics, Inc. (NEOS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRNA and NEOS operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for NEOS).
- Company
- Dicerna Pharmaceuticals, Inc.
- Neos Therapeutics, Inc.
- Price
- $38.23+0.61%
- -
- Market cap
- $2.96B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2015
- News (4w)
- 0
- 0
- Recent ratings
- 14
- 0
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company
Latest NEOS
- FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC
- FDA Approval for COTEMPLA XR-ODT issued to NEOS THERAPS INC
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form EFFECT filed by Neos Therapeutics, Inc.
- SEC Form 8-K filed by Neos Therapeutics, Inc.
- SEC Form 425 filed by Neos Therapeutics, Inc.
- SEC Form 4: M John Limongelli disposed to the issuer $0 worth of Common Stock (83,015 units at $0.00), decreasing direct ownership by 100% to 0 units
- SEC Form 4: Jr. A. James Robinson disposed to the issuer $0 worth of Common Stock (23,453 units at $0.00), decreasing direct ownership by 100% to 0 units